Maintaining Our Lexicon Fair Value Estimate Following Mixed 2017 Results
We’re maintaining our $9.70 fair value estimate for Lexicon following 2017 results, and while we’re adjusting some of our near-term operating expense assumptions, we’re still comfortable with our sales forecasts for the firm’s two key products. Carcinoid syndrome drug Xermelo saw more than $15 million in sales in the U.S. in 2017, and Lexicon expects the drug’s sales to at least double in 2018. While Xermelo’s launch has been disappointing, as Lexicon has struggled with higher discontinuation ra...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.